Awareness of nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD) is low among Americans who have risks associated with the diseases, according to a survey presented at the NASH Summit in Boston. Many clinical trials are currently underway regarding pharmacologic interventions in an area where diet and lifestyle are failing to curb rising incidence